Challenges in randomized controlled trials and emerging multiple sclerosis therapeutics

Area of Science:

• Neurology
• Immunology
• Clinical Trials

Background:

• Disease-modifying therapies (DMTs) have significantly improved multiple sclerosis (MS) management globally.
• Neurologists in North America and Europe offer multiple DMTs, leading to better patient outcomes and no evidence of disease activity.
• Ethical guidelines discourage placebo-controlled trials, necessitating active comparators and increasing trial complexity.

Purpose of the Study:

• To explore the landscape of multiple sclerosis (MS) treatment and clinical trials in Asia.
• To address the limitations in DMT accessibility in Asian countries.
• To evaluate the potential of Asia as a region for conducting MS clinical trials.

Main Methods:

• Review of global DMT development and clinical trial methodologies.
• Analysis of MS prevalence and patient characteristics in Asia.
• Examination of recent randomized controlled trials (RCTs) conducted in Asian regions.

Main Results:

• Despite a high prevalence of MS in Asia, access to approved DMTs is limited.
• Recent RCTs in Asia demonstrate successful participant recruitment and trial completion.
• Studies utilizing McDonald diagnostic criteria, excluding neuromyelitis optica (NMO), show Asian MS patients have clinical characteristics and treatment responses similar to Western patients.

Conclusions:

• Asia presents a significant opportunity for conducting clinical trials for new MS therapies due to a large patient population and limited access to current DMTs.
• Recent trial data suggest that MS in Asia shares clinical characteristics and treatment responses with Western MS.
• Further research and regulatory adjustments are needed to improve DMT accessibility for MS patients in Asia.